Menu
GWAS Study

Genome wide association study of clinical duration and age at onset of sporadic CJD.

Hummerich H, Speedy H, Campbell T et al.

39079175 PubMed ID
GWAS Study Type
3773 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

HH
Hummerich H
SH
Speedy H
CT
Campbell T
DL
Darwent L
HE
Hill E
CS
Collins S
SC
Stehmann C
KG
Kovacs GG
GM
Geschwind MD
FK
Frontzek K
BH
Budka H
GE
Gelpi E
AA
Aguzzi A
VD
van der Lee SJ
VD
van Duijn CM
LP
Liberski PP
CM
Calero M
SP
Sanchez-Juan P
BE
Bouaziz-Amar E
LJ
Laplanche JL
HS
Haïk S
BJ
Brandel JP
MA
Mammana A
CS
Capellari S
PA
Poleggi A
LA
Ladogana A
PM
Pocchiari M
ZS
Zafar S
BS
Booth S
JG
Jansen GH
AA
Areškevičiūtė A
LL
Løbner Lund E
GK
Glisic K
PP
Parchi P
HP
Hermann P
ZI
Zerr I
AB
Appleby BS
SJ
Safar J
GP
Gambetti P
CJ
Collinge J
MS
Mead S
Chapter II

Abstract

Summary of the research findings

Human prion diseases are rare, transmissible and often rapidly progressive dementias. The most common type, sporadic Creutzfeldt-Jakob disease (sCJD), is highly variable in clinical duration and age at onset. Genetic determinants of late onset or slower progression might suggest new targets for research and therapeutics. We assembled and array genotyped sCJD cases diagnosed in life or at autopsy. Clinical duration (median:4, interquartile range (IQR):2.5-9 (months)) was available in 3,773 and age at onset (median:67, IQR:61-73 (years)) in 3,767 cases. Phenotypes were successfully transformed to approximate normal distributions allowing genome-wide analysis without statistical inflation. 53 SNPs achieved genome-wide significance for the clinical duration phenotype; all of which were located at chromosome 20 (top SNP rs1799990, pvalue = 3.45x10-36, beta = 0.34 for an additive model; rs1799990, pvalue = 9.92x10-67, beta = 0.84 for a heterozygous model). Fine mapping, conditional and expression analysis suggests that the well-known non-synonymous variant at codon 129 is the obvious outstanding genome-wide determinant of clinical duration. Pathway analysis and suggestive loci are described. No genome-wide significant SNP determinants of age at onset were found, but the HS6ST3 gene was significant (pvalue = 1.93 x 10-6) in a gene-based test. We found no evidence of genome-wide genetic correlation between case-control (disease risk factors) and case-only (determinants of phenotypes) studies. Relative to other common genetic variants, PRNP codon 129 is by far the outstanding modifier of CJD survival suggesting only modest or rare variant effects at other genetic loci.

3,773 European ancestry cases

Chapter III

Study Statistics

Key metrics and study information

3773
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Canada, Austria, Netherlands, U.S., Poland, Italy, U.K., Australia, France, Switzerland, Germany, Spain
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.